BAX

Analyzing Baxter International's Surge in Stock Price.

This morning we watched Baxter International rise 6.6% to a price of $36.92 per share. The Large-Cap Medical Instruments & Supplies company is now trading -12.1% below its average target price of $42.0. Analysts have set target prices ranging from $30.0 to $54.0 per share for Baxter International, and have given the stock an average rating of hold.

Baxter International's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.3%. The stock's short ratio is 1.89. The company's insiders own 0.38% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 94.1%. In conclusion, we believe there is mixed market sentiment regarding Baxter International.

Institutions Invested in Baxter International

Date Reported Holder Percentage Shares Value
2024-03-31 Blackrock Inc. 12% 60,964,852 $2,250,822,224
2024-03-31 Vanguard Group Inc 12% 59,747,560 $2,205,879,805
2024-06-30 Pzena Investment Management Llc 6% 30,823,004 $1,137,985,251
2024-03-31 Dodge & Cox Inc 5% 27,501,895 $1,015,369,913
2024-03-31 State Street Corporation 4% 21,341,504 $787,928,288
2024-03-31 Price (T.Rowe) Associates Inc 3% 16,675,915 $615,674,751
2024-03-31 Ameriprise Financial, Inc. 3% 15,218,422 $561,864,112
2024-03-31 JP Morgan Chase & Company 2% 11,607,134 $428,535,366
2024-03-31 Geode Capital Management, LLC 2% 11,455,910 $422,952,176
2024-03-31 Harris Associates L.P. 2% 9,972,284 $368,176,707
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS